Miip-KO Mouse
Common Name
Miip-KO
제품 ID
S-KO-08986
Backgroud
C57BL/6JCya
품종 계통계통 ID
KOCMP-28010-Miip-B6J-VB
상태
이 마우스 계통을 논문에서 사용할 경우, “Miip-KO Mouse (카탈로그 번호 S-KO-08986)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Miip-KO
품종 계통계통 ID
KOCMP-28010-Miip-B6J-VB
유전자명
제품 ID
S-KO-08986
유전자 별칭
IIP45, D4Wsu114e
배경
C57BL/6JCya
NCBI ID
변형 내용
Conventional knockout
염색체
Chr 4
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000030886
NCBI 전사체 ID
NM_001025365
타겟 영역
Exon 5~8
유효 영역 크기
~2.0 kb
유전자 연구 개요
MIIP, also known as migration and invasion inhibitory protein, is a gene that functions as a tumor-suppressor in various cancers [3]. It plays a role in regulating multiple biological processes. MIIP is involved in pathways related to cell migration, invasion, and mitosis, and is associated with the cytoskeleton system, as it can regulate microtubules by interacting with HDAC6 [3].
In hepatocellular carcinoma (HCC), MIIP expression is decreased, and low MIIP expression is associated with distant metastasis and poor prognosis. MIIP can inhibit the malignant progression of HCC by regulating AKT expression [1]. In colorectal cancer, MIIP down-regulation drives cancer progression through inducing peri-cancerous adipose tissue browning. MIIP interacts with AZGP1, regulating its glycosylation and secretion, which in turn promotes adipose browning and CRC cell proliferation [2]. In triple-negative breast cancer, MIIP is a favorable prognostic indicator, inhibiting tumor angiogenesis, proliferation, and metastasis by interacting with ITGB3 and suppressing its downstream signaling [4]. In clear cell renal cell carcinoma, MIIP inhibits proliferation and angiogenesis via negative modulation of the HIF-2α-CYR61 axis [5]. In prostate cancer, MIIP inhibits EMT and cell invasion through the miR-181a/b-5p-KLF17 axis, and also inhibits growth via interaction with PP1α and negative modulation of AKT signaling [6,8]. In endometrial cancer, MIIP functions as a tumor suppressor, attenuating Rac1 signaling and remodeling the cytoskeleton to suppress metastasis [7]. In nasopharyngeal carcinoma, MIIP expression is associated with radiosensitivity [9]. In esophageal squamous cell carcinoma, MIIP expression is higher in cancer tissues than in paracancerous normal epithelia and is an independent prognostic factor [10].
In conclusion, MIIP plays a crucial role in inhibiting the progression of multiple cancers. Model-based research, especially gene knockout or knockdown experiments in cell lines as described in these studies, has revealed its role in regulating key cellular processes related to cancer development. Understanding MIIP's function provides potential targets for cancer treatment and prognosis prediction.
References:
1. Fang, J, Chen, Y-L, Yao, H-B, Yang, P, Ding, Z-Y. . MIIP inhibits malignant progression of hepatocellular carcinoma through regulating AKT. In European review for medical and pharmacological sciences, 24, 2335-2346. doi:10.26355/eurrev_202003_20500. https://pubmed.ncbi.nlm.nih.gov/32196585/
2. Wang, Qinhao, Su, Yuanyuan, Sun, Ruiqi, Qiao, Qing, Li, Xia. 2024. MIIP downregulation drives colorectal cancer progression through inducing peri-cancerous adipose tissue browning. In Cell & bioscience, 14, 12. doi:10.1186/s13578-023-01179-0. https://pubmed.ncbi.nlm.nih.gov/38245780/
3. Wang, Yingmei, Wen, Jing, Zhang, Wei. . MIIP, a cytoskeleton regulator that blocks cell migration and invasion, delays mitosis, and suppresses tumorogenesis. In Current protein & peptide science, 12, 68-73. doi:. https://pubmed.ncbi.nlm.nih.gov/21190522/
4. Gao, Yujing, Fang, Yujie, Huang, Yongli, Shan, Jingxuan, Li, Pu. 2022. MIIP functions as a novel ligand for ITGB3 to inhibit angiogenesis and tumorigenesis of triple-negative breast cancer. In Cell death & disease, 13, 810. doi:10.1038/s41419-022-05255-0. https://pubmed.ncbi.nlm.nih.gov/36130933/
5. Yan, Fengqi, Wang, Qinhao, Xia, Mingyuan, Wu, Guojun, Li, Xia. . MIIP inhibits clear cell renal cell carcinoma proliferation and angiogenesis via negative modulation of the HIF-2α-CYR61 axis. In Cancer biology & medicine, 19, 818-35. doi:10.20892/j.issn.2095-3941.2020.0296. https://pubmed.ncbi.nlm.nih.gov/34931765/
6. Hu, Wei, Yan, Fengqi, Ru, Yi, Li, Xia, Wang, Qinhao. 2020. MIIP inhibits EMT and cell invasion in prostate cancer through miR-181a/b-5p-KLF17 axis. In American journal of cancer research, 10, 630-647. doi:. https://pubmed.ncbi.nlm.nih.gov/32195032/
7. Wang, Yingmei, Hu, Limei, Ji, Ping, Xue, Fengxia, Zhang, Wei. 2016. MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. In Journal of hematology & oncology, 9, 112. doi:10.1186/s13045-016-0342-6. https://pubmed.ncbi.nlm.nih.gov/27760566/
8. Yan, Guang, Ru, Yi, Yan, Fengqi, Wang, Qinhao, Li, Xia. 2019. MIIP inhibits the growth of prostate cancer via interaction with PP1α and negative modulation of AKT signaling. In Cell communication and signaling : CCS, 17, 44. doi:10.1186/s12964-019-0355-1. https://pubmed.ncbi.nlm.nih.gov/31092266/
9. Zhou, Hong-Ping, Qian, Lu-Xi, Zhang, Nan, He, Xia, Yin, Li. 2018. MIIP gene expression is associated with radiosensitivity in human nasopharyngeal carcinoma cells. In Oncology letters, 15, 9471-9479. doi:10.3892/ol.2018.8524. https://pubmed.ncbi.nlm.nih.gov/29805670/
10. Wen, Jing, Liu, Qian-Wen, Luo, Kong-Jia, Hu, Yi, Fu, Jian-Hua. 2016. MIIP expression predicts outcomes of surgically resected esophageal squamous cell carcinomas. In Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 37, 10141-8. doi:10.1007/s13277-015-4633-2. https://pubmed.ncbi.nlm.nih.gov/26825982/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
